As Demand for RBx Soars CluePoints Continues Global Expansion Alongside Further Award Wins
CluePoints, the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software for clinical trials, today announced major expansion as it bolsters its offering with two new larger offices to accommodate its growing family of employees and contractors. This coincides with another distinction which saw CluePoints scoop Scale up of the Year (Most Promising Company of the Year) at the recent 2019 EY Belgium awards. The move to larger premises located in King of Prussia, US and Louvain-la-Neuve, Belgium, creates an extra 3,111 square feet to accommodate growth and an increase in employee numbers.
Demand for CluePoints’ software and services has fueled a fresh wave of expansion in the US and Belgium. Commenting on the growth and EY Belgium accolade, Patrick Hughes, Chief Commercial Officer of CluePoints said, “We’re not resting on our laurels. The move to bigger premises is a testament to our exponential success as a company and our continued investment both in the product suite and our valued client partners. We have increased our employee base as we needed to scale-up to accommodate the increased demand for our services and also to facilitate the significant growth we have slated for 2020 and beyond. We have a clear roadmap for the business, and we are all looking forward to the months ahead. We’re delighted to be recognised for our continued innovation, transparency and quality which are the keys to our success”
The company’s vision of RBx, where data, metrics and actions become reusable knowledge, has captured the imagination of the industry. As a result, 9 new appointments have been made in the last three months alone, adding to a dedicated team of relationship managers, subject matter experts, and data analysts, mandating the need to increase office capacity. Servicing clients across the globe, the team has grown to over 70 working across 2 offices, and the company’s turnover reflects record growth this year.
CluePoints is committed to helping companies identify, assess, plan, mitigate, monitor and analyze risk across all elements of clinical trial management to comply with regulatory requirements. The new premises provide a space for Pharma and CEO companies to perform audit work on site. “Our partnership approach to supporting clients, combined with a proactive culture and strong core values, make it easy for our clients to utilize our office space and do business with us,” continued Patrick Hughes. “Our new offices and increase in employee numbers provide an excellent foundation for continued growth. Our new team members are a talented group of individuals and join an established team that serves clients across the globe.”
King of Prussia and Louvain-la-Neuve are fast-growing business communities. The new locations are well situated for staff and clients alike, as they are close to excellent travel networks and local amenities. CluePoints continues to drive the paradigm shift towards an entirely different Risk-Based Approach to Study Execution (RBx) from pre-study risk assessment, through risk identification and control to final auditable documentation. All elements of trial management can be done with a risk-based approach, aligned with ICH E6 (R2) and other key industry guidelines.
CluePoints recently announced that the FDA has extended their CRADA until October 2021 and continuing the company’s success, CluePoints has also been selected as finalists for two prestigious awards - The European Innovation Awards and SCRIP Awards for their Risk-Based Study Execution (RBx) and Data Quality Oversight Software for Clinical Trials. CluePoints were also announced recently as winners of the 2019 GHP Healthcare & Pharmaceutical Awards for Most Pioneering RBM Software Company.
For further information on CluePoints' solutions, please visit www.cluepoints.com
CluePoints is the premier provider of Risk-Based Study Execution (RBx) and Data Quality Oversight Software. Our products utilize comprehensive statistical algorithms to determine the quality, accuracy, and integrity of clinical trial data both during and after study conduct. Aligned with guidance from the FDA, EMA, and ICH E6 (R2), CluePoints® is deployed to support central and on-site monitoring, medical review, quality risk management and to drive a holistic Risk-Based strategy in all trials. Coupled with thought leadership and consulting expertise to aid pre-study risk assessment, identification of risk controls and solution implementation you now have everything you need to adhere with global regulatory guidance. The result is increased operational efficiency, lower costs and reduced regulatory submission risk as part of the industry paradigm shift to RBx.
Patrick Hughes - Chief Commercial Officer, CluePoints
+44 (0) 7703 532 749